In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Latest Uproar in Generics:180-day Exclusivity

Executive Summary

Legal strategies are getting ever more sophisticated in the war between generics and brand-name companies. Some generics companies are in an uproar about a new wrinkle in their efforts to bring lower-priced drugs to market; because of a series of court decisions that upset an FDA practice, generics companies that are first to file for approval of a drug in which they think the patent may be challenged are entitled to 6 months market exclusivity. Previously, the FDA required a lawsuit to be underway in order for generics companies to get exclusivity, but now, a company can get the exclusivity just by making the claim that they might be subjected to a lawsuit. Generics companies worry that their competitors will take advantage of the policy by rushing to file sub-standard ANDAs just to be able to get the market exclusivity; in addition, they might try to strike deals with brand name companies that would give them a reward for keeping other generics companies off the market entirely.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts